1. Disposable casing for thermally insulated walls in reinforced concrete, the casing comprising two main panels facing each other and limited from the outside by respective lateral surfaces, and at least two casing spacers interposed between the two main panels to maintain the two main panels at a pre-determined distance from each other; the casing comprising at least one supplementary panel arranged abutting the lateral surface of a respective main panel, and connecting means interposed between the supplementary panel and the relative main panel to render the supplementary panel and the main panel integral in relation to each other.
2. Disposable casing according to claim 1, wherein said two main panels have a standard thickness and said supplementary panel has a thickness adapted according to installation needs.
3. Disposable casing according to claim 1, comprising two supplementary panels arranged abutting the lateral surfaces of said two main panels.
4. Disposable casing according to claim 1, wherein the main panel and the supplementary panel are made of the same material.
5. Disposable casing according to claim 1, wherein said connecting means comprise a plurality of shaped projections integral with the main panel or with the supplementary panel, and, for each shaped projection, respective undercuts obtained on an associated supplementary panel or the main panel.
6. Disposable casing according to claim 5, wherein said shaped projections are defined by respective dovetailed moldings extending an entire height of the main panel or the supplementary panel.
7. Disposable casing according to claim 1, wherein said connecting means are defined by a layer of adhesive material interposed between the main panel and an associated supplementary panel.
8. Disposable casing according to claim 1, wherein said casing spacers are provided with respective hinges to permit the collapse of the casing into a transport configuration.
9. Disposable casing according to claim 1, wherein said casing spacers are provided with detachable elements to permit the supply of the casing in an un-assembled configuration.
10. Disposable casing according to claim 4, wherein the main panel and the supplementary panel are made of polystyrene.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for treating platinum drugs induced vestibulotoxicity, comprising administering a compound that impairs or prevents accumulation of platinum drugs within vestibular hair cells andor vestibular primary neurons.
2. The method according to claim 1, wherein said compound promote the protection,
survival or regeneration of the vestibular hair cells andor vestibular primary neurons.
3. The method according to claim 1, wherein the platinum drugs are cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, tetraplatin, transplatin, nedaplatin, ormaplatin, PtCl2R,R-DACH, pyriplatin, ZD0473, BBR3464 or Pt-1C3.
4. The method according to claim 1, wherein said compound modulates platinum drugs flux through vestibular hair cells andor vestibular primary neurons, or impairs or reduces the influx or uptake of platinum drugs in vestibular cells andor vestibular primary neurons, or impairs or increases the efflux of platinum drugs in the vestibular hair cells andor vestibular primary neurons.
5. The method according to claim 1, wherein said compound is an OCT (organic cations transporter) inhibitor, a CTR (copper transporters) inhibitor, a MATE (multidrug and toxin extrusion) transporters activator, a MRP (multidrug resistance associated protein) transporters activator, or an ATP7A or ATP7B transporters activator.
6. The method according to claim 1, wherein said compound is cimetidine, linagliptin, amantadine, memantine, agmatine, chlorpromazine, doxepin, erlotinib, gefitinib, metformin, amitriptyline, carvedilol, chloroquine, clonidine, desloratadine, diphenhydramine, disopyramide, fenfluramine, flecainide, flurazepam, imipramine, ipratropiumbromide, levomethadone, mefloquine, mexiletine, propafenone, propranolol, quinidine, sibutramine, tamoxifen, trimethoprim, verapamil, imatinib, and 6\u03b2-hydroxycortisol, collagen\u03b21 integrin, lipopolysaccharide (LPS), copper sulphate, 4-phenylbutyrate (4-PBA), curcumin, nizatidine, ranitidine, pantoprazole, rabeprazole, lansoprazole or omeprazole.
7. The method according to claim 1, wherein said compound is cimetidine, nizatidine, ranitidine, pantoprazole, rabeprazole, lansoprazole or omeprazole.